MRKR Bio Penny Stock High Risk Reward/Loss Triple Play
Summary
- May 2021, TPIV200 Phase 2 potential results for clinical trial; NCT02764333.Platinum Resistant Ovarian Cancer.
- Dec 2021, TPIV200 Phase 2 potential results for clinical trial; NCT02593227.Triple Negative Breast Cancer.
- July 2022, MT-401 Phase 2 potential results for clinical trial; NCT04511130MT.T-Cells.Acute Myeloid Leukemia.
MRKR is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications.
With the FDA Partial clinical hold now lifted on MRKR's MT-401 Phase 2 trial there are now three possible rally catalysts for this stock in 2021:
- May 2021, TPIV200 Phase 2 potential results for clinical trial; NCT02764333...Platinum Resistant Ovarian Cancer.
- Dec 2021, TPIV200 Phase 2 potential results for clinical trial; NCT02593227...Triple Negative Breast Cancer...
- July 2022, MT-401 Phase 2 potential results for clinical trial; NCT04511130MT...T-Cells...Acute Myeloid Leukemia.
This is a sell the news play because any immunotherapies that MRKR develops will not likely to be commercially available for at least five years. This is a good long term risk play if your time horizon is more than 5 years.
Analyst's Disclosure: I am/we are long MRKR.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.